89Zr-DFO-girentuximab (Zircaix, TLX250-CDx): FDA status

Decision date passed Indication: PET imaging of clear cell renal cell carcinoma. Company: Telix Pharmaceuticals.

Regulatory history

All products in the FDA Tracker

Loading today's edition…